Fig. 3: Integration of B cells from CBCL samples with B cells from MALT, sFCL, sDLBCL, and reactive lymph nodes.

a Overview of processed samples. Created in BioRender. Griss, J. (2026) https://BioRender.com/8i86vna. b UMAP embedding of all processed B cells (cutaneous and systemic lymphomas). c Disease of origin of the processed B cells. d Distribution of B cell phenotypes of topclone per sample grouped by disease. e Dot plot showing the abundance of immunoglobulin isotype genes in the top expanded clone per sample. f Dot plot showing expression values of genes differentially expressed between indolent cutaneous entities (rB-LP, pcMZL, pcFCL) and the other entities. g Visual representation of the canonical B cell trajectory and the respective distribution of the top expanded clones per disease. Created in BioRender. Griss, J. (2026) https://BioRender.com/8p4kb6z. h Relative proportion of the top expanded clone per sample (n = 49) and disease. Values are normalised based on the total number of B cells. Stars represent significant levels based on a two-sided Wilcoxon rank sum test with FDR correction (*<0.01, **<0.05, n.s. >0.05). Adjusted p-values for the comparison against pcMZL were 0.06 (rB-LP), 0.014 (pcFCL), 0.004 (pcDLBCL-LT, MALT, sDLBCL), and 0.003 (sFCL). Lower and upper hinges of the boxplots correspond to the first and third quartiles, centre represents the median, whiskers extend to a maximum of 1.5 of the interquartile range and represent the minimum and maximum value within this range. i Dot plot showing expression values of genes differentially expressed between pcDLBCL-LT and sDLBCL and other entities. Source data are provided as a Source Data file.